Intellia Therapeutics, Inc. (NTLA)
12.26
+0.14
(+1.16%)
USD |
NASDAQ |
Oct 02, 16:00
12.16
-0.10
(-0.82%)
After-Hours: 20:00
Intellia Therapeutics Net Income (Quarterly) : -106.63M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -106.63M |
| March 31, 2026 | -96.23M |
| December 31, 2025 | -95.79M |
| September 30, 2025 | -101.32M |
| June 30, 2025 | -101.26M |
| March 31, 2025 | -114.33M |
| December 31, 2024 | -128.90M |
| September 30, 2024 | -135.71M |
| June 30, 2024 | -146.98M |
| March 31, 2024 | -107.44M |
| December 31, 2023 | -132.16M |
| September 30, 2023 | -122.22M |
| June 30, 2023 | -123.68M |
| March 31, 2023 | -103.13M |
| December 31, 2022 | -113.41M |
| September 30, 2022 | -113.23M |
| June 30, 2022 | -100.68M |
| March 31, 2022 | -146.87M |
| December 31, 2021 | -81.24M |
| September 30, 2021 | -71.64M |
| June 30, 2021 | -68.81M |
| Date | Value |
|---|---|
| March 31, 2021 | -46.20M |
| December 31, 2020 | -42.19M |
| September 30, 2020 | -27.84M |
| June 30, 2020 | -32.39M |
| March 31, 2020 | -31.81M |
| December 31, 2019 | -28.28M |
| September 30, 2019 | -23.63M |
| June 30, 2019 | -25.68M |
| March 31, 2019 | -21.94M |
| December 31, 2018 | -19.07M |
| September 30, 2018 | -22.70M |
| June 30, 2018 | -22.22M |
| March 31, 2018 | -21.36M |
| December 31, 2017 | -23.96M |
| September 30, 2017 | -15.36M |
| June 30, 2017 | -15.59M |
| March 31, 2017 | -12.63M |
| December 31, 2016 | -10.56M |
| September 30, 2016 | -7.482M |
| June 30, 2016 | -6.90M |
| March 31, 2016 | -6.689M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Beam Therapeutics, Inc. | -122.68M |
| Twist Bioscience Corp. | -35.05M |
| Prime Medicine, Inc. | -42.11M |
| Moderna, Inc. | -782.00M |
| Q32 Bio, Inc. | -8.946M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.659M |
| Total Expenses (Quarterly) | 114.29M |
| EPS Diluted (Quarterly) | -0.7989 |
| Enterprise Value | 1.352B |
| Gross Profit Margin (Quarterly) | 72.58% |
| Profit Margin (Quarterly) | -1.39K% |
| Earnings Yield | -27.38% |
| Normalized Earnings Yield | -27.35 |